Homing Post Injury - ExoPTEN
NurExone Demonstrates Extended Therapeutic Window of ExoPTEN Post Spinal-Cord Injury in Preclinical Study
06. September 2024 16:03 ET | NurExone Biologic Inc
NurExone demonstrates a longer timeframe of ExoPTEN treatment can be effectively administered post Spinal-Cord Injury
2024_Process Robustness
NurExone Biologic Achieves Key Milestone in Support of Robust Exosome Manufacturing Process
15. August 2024 16:03 ET | NurExone Biologic Inc
NurExone’s reliable production from diverse biological sources allows NurExone to optimize exosome production with consistency and efficiency
Figure 1
NurExone's ExoPTEN, loaded with siRNA, Demonstrates Ability to Target Injury and Inflammation Sites – New Study
09. August 2024 16:04 ET | NurExone Biologic Inc
NurExone announces promising new data for its ExoPTEN nanodrug, highlighting progress towards commercial-grade manufacturing
Inotiv_Logo_CMYK.png
Inotiv, Inc. Enhances Histopathology Offering with Announcement of Agreement to Purchase HistoTox Labs, Inc.
13. April 2021 16:35 ET | Inotiv, Inc.
WEST LAFAYETTE, Ind., April 13, 2021 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading provider of nonclinical and analytical contract research...